Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) reported new clinical data on its FDA-cleared Vida® oral appliance for patients with longstanding moderate to severe insomnia.
In a 37-patient single-site study, average Insomnia Severity Index scores fell about 65%, with 100% improving at least one severity level and ending with no or subthreshold insomnia (p≈0.0000001). Vivos sees a potential new insomnia revenue stream, including an estimated $36 million annual addressable market at Sleep Centers of Nevada alone, though it notes the data are early and insomnia-related findings are not FDA-reviewed.
Vivos Therapeutics (NASDAQ: VVOS) extended its strategic financing agreement with Streeterville Capital through August 31, 2026.
Streeterville reaffirmed its commitment to convert up to $4.5 million of debt into a mix of perpetual, non-convertible preferred stock and common stock once Vivos raises $2.6 million, supporting Nasdaq listing compliance and a planned rights offering.
Vivos Therapeutics (NASDAQ: VVOS) plans to file a registration statement with the SEC for a proposed transferable rights offering. Shareholders of record, 30 days after SEC effectiveness, are expected to receive rights as a dividend.
Each right is expected to allow purchase of one common share at the greater of $1.25 or 20% above market, be listed for trading, and be exercisable for nine months. Exercising a right is expected to grant a subsequent nine‑month right with an exercise price set at the greater of $1.75 or 40% above market. Completion depends on multiple conditions, and Vivos notes there is no assurance the offering will commence or be completed.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, a management services organization focused on diagnosing and treating obstructive sleep apnea and insomnia in cardiovascular patients.
Vivos expects to own at least 80% of AIM Florida, with SPCVA up to 20%. The initial Sleep Optimization Team is planned to serve about 250 patients per month and is projected to generate over $6 million in annual revenue with contribution margins approaching 50%, based on Vivos’ prior Las Vegas experience. Operations will initially target Palm Beach County, with potential expansion across Florida and to other cardiology and specialty practices, subject to definitive agreements and regulatory compliance.
Vivos Therapeutics (NASDAQ: VVOS) announced that its executive team will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City.
CEO Kirk Hunstman will present at 11:30 am ET, with a live and replay webcast available via the company’s investor relations website.
Vivos Therapeutics (NASDAQ: VVOS) agreed with senior lender Streeterville Capital to exchange up to $4.5 million of debt into perpetual, nonconvertible preferred stock and common shares. The exchange, contingent on qualifying equity financings, is intended to bolster stockholders’ equity, support Nasdaq listing compliance, and reduce debt service.
Streeterville committed to suspend debt repayment calls for 90 days and sales of Vivos securities for 60 days after the exchange becomes effective, which is expected to assist cash flow and liquidity.
Vivos Therapeutics (NASDAQ: VVOS) reported first quarter 2026 revenue of approximately $5.1 million, up 70% year over year, driven mainly by sleep testing services and its SCN acquisition. Gross profit rose to $3.1 million with a 60% gross margin, while net loss widened to $7.8 million.
Operating expenses increased to $9.7 million, including about $0.9 million in non-recurring professional fees. Oral appliance unit sales grew 42% to 5,304, though legacy VIP appliance revenue declined. Cash was $2.1 million and stockholders’ equity showed a $1.1 million deficit at March 31, 2026.
Vivos Therapeutics (NASDAQ: VVOS) reported full year 2025 revenue of $17.5 million, up 16% from 2024, driven by sleep testing services and the June 2025 acquisition of The Sleep Center of Nevada (SCN). Gross profit rose to $10.5 million with a 60% gross margin. Operating loss widened to $19.9 million on higher operating expenses of $30.4 million. Cash was $2.0 million at year-end, later supplemented by $6.8 million in post-year financings. Management cited a strategic pivot to acquisitions and alliances and will host a conference call on April 15, 2026.
Vivos Therapeutics (NASDAQ: VVOS) will release its full year 2025 financial results after market close on April 15, 2026 and hold a conference call the same day at 5:00 pm ET.
Management will review results, discuss strategic collaborations, and provide operational updates. A live webcast and a replay (passcode 1153783) will be available; the replay is accessible until April 29, 2026 and the webcast archive for 30 days.
Vivos Therapeutics (NASDAQ: VVOS) closed a private placement with New Seneca affiliate V-Co 3, raising $2.25 million (includes conversion of a prior $1.4 million bridge note) on March 31, 2026. Vivos issued common stock, a pre-funded warrant, and 2- and 5-year warrants exercisable at $1.09.
V-Co 3 paid $1.34 per share/warrant; aggregate Seneca investments since 2024 total $13.4 million. Vivos recorded an original issue discount of $140,000 and intends to use net proceeds for general working capital while pursuing its medical affiliation model and breakeven cash flow goal by end of 2026.